{
    "2019-10-10": [
        [
            {
                "time": "2018-10-15",
                "original_text": "Hereâ€™s What Hedge Funds Think About Eli Lilly and Company (LLY)",
                "features": {
                    "keywords": [
                        "Hedge Funds",
                        "Eli Lilly",
                        "LLY"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-10-16",
                "original_text": "3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates",
                "features": {
                    "keywords": [
                        "Drug",
                        "Biotech",
                        "Q3 Earnings",
                        "Estimates"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-17",
                "original_text": "J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector",
                "features": {
                    "keywords": [
                        "J&J",
                        "JNJ",
                        "Q3 Earnings",
                        "Pharma Sector"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-18",
                "original_text": "Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study",
                "features": {
                    "keywords": [
                        "Dermira",
                        "Lebrikizumab",
                        "Eczema",
                        "Late-Stage Study"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}